Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6893562 | 0.88 | ALDH1A1 (0.46) | POLBALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL16116734 | 0.81 | ALDH1A1 (0.42) | POLBALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL31318714 | 0.75 | MAPT (0.46) | POLBALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL21822034 | 0.75 | NPC1 (0.46) | ALDH1A1MEN1KMT2ACASP3NPC1 | |
| SCHEMBL3923679 | 0.74 | KMT2A (0.47) | POLBALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL4336939 | 0.74 | HPGD (0.61) | POLBALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL9832087 | 0.74 | ALDH1A1 (0.43) | POLBALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL21777188 | 0.72 | MEN1 (0.38) | POLBALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL7191424 | 0.70 | HTT (0.43) | ALDH1A1TDP1MEN1KMT2ARAB9A | |
| SCHEMBL22216178 | 0.69 | MAPT (0.52) | POLBALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528802-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-20220274982-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-01 | — | — | US | disclosed |
| EP-4005638-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528802-B2 | Heterocyclic compound | GBA2, GBA1, GALC | POLB 3518/4885ALDH1A1 2563/4885TDP1 1860/4885 |
| US-20220274982-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | POLB 3724/4885ALDH1A1 1563/4885TDP1 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.